Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis

References

• OlnesMJErlichRA review and update on cholangiocarcinomaOncology200466316717915218306
   PubMed Web of Science ®Google Scholar
• PatelTCholangiocarcinomaNat Clin Pract Gastroenterol Hepatol200631334216397610
   PubMedGoogle Scholar
• TysonGLEl-SeragHBRisk factors for cholangiocarcinomaHepatology201154117318421488076
   PubMed Web of Science ®Google Scholar
• VautheyJNBlumgartLHRecent advances in the management of cholangiocarcinomasSemin Liver Dis19941421091148047893
   PubMed Web of Science ®Google Scholar
• ShaibYEl-SeragHBThe epidemiology of cholangiocarcinomaSemin Liver Dis200424211512515192785
   PubMed Web of Science ®Google Scholar
• Taylor-RobinsonSDToledanoMBAroraSIncrease in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998Gut200148681682011358902
   PubMed Web of Science ®Google Scholar
• ShaibYHDavilaJAMcglynnKEl-SeragHBRising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?J Hepatol200440347247715123362
   PubMed Web of Science ®Google Scholar
• LepageCCottetVChauvenetMTrends in the incidence and management of biliary tract cancer: a French population-based studyJ Hepatol201154230631021056501
   PubMed Web of Science ®Google Scholar
• KhanSAThomasHCDavidsonBRTaylor-RobinsonSDCholangiocarcinomaLancet200536694931303131416214602
   PubMed Web of Science ®Google Scholar
• CaiHKongWTChenCBCholelithiasis and the risk of intra-hepatic cholangiocarcinoma: a meta-analysis of observational studiesBMC Cancer20151583126526500
   PubMed Web of Science ®Google Scholar
• PalmerWCPatelTAre common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinomaJ Hepatol2012571697622420979
   PubMed Web of Science ®Google Scholar
• WelzelTMGraubardBIEl-SeragHBRisk factors for intra-hepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control studyClin Gastroenterol Hepatol20075101221122817689296
   PubMed Web of Science ®Google Scholar
• ShaibYHEl-SeragHBNookaAKRisk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control studyAm J Gastroenterol200710251016102117324130
   PubMed Web of Science ®Google Scholar
• ShaibYHEl-SeragHBDavilaJAMorganRMcglynnKARisk factors of intrahepatic cholangiocarcinoma in the United States: a case-control studyGastroenterology2005128362062615765398
   PubMed Web of Science ®Google Scholar
• GuptaADixonEEpidemiology and risk factors: intrahepatic cholangiocarcinomaHepatobiliary Surg Nutr20176210110428503557
   PubMed Web of Science ®Google Scholar
• HayashiNYamamotoHHiraokaNDifferential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasmHepatology2001344 Pt163865011584358
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA StatementOpen Med200933e12313021603045
   PubMedGoogle Scholar
• StroupDFBerlinJAMortonSCMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) groupJAMA2000283152008201210789670
   PubMed Web of Science ®Google Scholar
• StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360520652370
   PubMed Web of Science ®Google Scholar
• ZhangYPLiWQSunYLZhuRTWangWJSystematic review with meta-analysis: coffee consumption and the risk of gallstone diseaseAliment Pharmacol Ther201542663764826198295
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBr Med J199731571096296349310563
   PubMed Web of Science ®Google Scholar
• StuckAERubensteinLZWielandDBias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneityBr Med J19983167129469469
   PubMed Web of Science ®Google Scholar
• XiongJLinJWangATea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studiesOncotarget2017824396493965728454105
   PubMedGoogle Scholar
• Long-term use of aspirin linked to reduced risk of developing bile duct cancerNurs Stand2016303815
   Google Scholar
• FriisSPoulsenAHJohnsenSPCancer risk among statin users: a population-based cohort studyInt J Cancer2005114464364715578694
   PubMed Web of Science ®Google Scholar
• Cichoz-LachHCelińskiKCan nonsteroidal anti-inflammatory drugs favourably affect the alimentary canal?Ann Univ Mariae Curie Sklodowska Med200257239940212898869
   PubMedGoogle Scholar
• MorganGBeneficial effects of NSAIDs in the gastrointestinal tractEur J Gastroenterol Hepatol199911439340010321755
   PubMed Web of Science ®Google Scholar
• SakodaLCGaoYTChenBEProstaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, ChinaCarcinogenesis20062761251125616361272
   PubMed Web of Science ®Google Scholar
• TalboysRJBurrNSavvaSThe role of non-steroidal anti-inflammatory drugs and statins in the aetiology of cholangiocarcinoma: preliminary results from a case control study in two UK centresGas-troenterology20111405S-595
   Web of Science ®Google Scholar
• BurrNETalboysRJSavvaSAspirin may prevent cholangiocarcinoma: a case-control study from the United kingdomDig Dis Sci20145971567157224535250
   PubMed Web of Science ®Google Scholar
• ChoiJGhozHMPeeraphatditTAspirin use and the risk of cholangiocarcinomaHepatology201664378579626940227
   PubMed Web of Science ®Google Scholar
• GraingeMJWestJSolaymani-DodaranMAithalGPCardTRThe antecedents of biliary cancer: a primary care case-control study in the United KingdomBr J Cancer2009100117818019018260
   PubMed Web of Science ®Google Scholar
• LiuESakodaLCGaoYTAspirin use and risk of biliary tract cancer: a population-based study in Shanghai, ChinaCancer Epidemiol Biomarkers Prev20051451315131815894693
   PubMed Web of Science ®Google Scholar
• PengYCLinCLHsuWYStatins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control studyBr J Clin Pharmacol201580475576125808421
   PubMed Web of Science ®Google Scholar
• AltaiiHAl-KindiSGOliveiraGHYaqoobZRomero-MarreroCAspirin use and risk of cholangiocarcinoma: external validation with big dataHepatology20176541421142228052348
   PubMed Web of Science ®Google Scholar
• PetrickJLSahasrabuddheVVChanATNSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling projectCancer Prev Res201581211561162
   PubMed Web of Science ®Google Scholar
• CooganPFRosenbergLPalmerJRNonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowelCancer Epidemiol Biomarkers Prev20009111912310667472
   PubMed Web of Science ®Google Scholar
• FlossmannERothwellPMEffect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet2007369957316031613
   PubMed Web of Science ®Google Scholar
• HochmuthFJochemMSchlattmannPMeta-analysis of aspirin use and risk of lung cancer shows notable resultsEur J Cancer Prev201625425926826067033
   PubMed Web of Science ®Google Scholar
• CaoYNishiharaRWuKPopulation-wide impact of long-term use of aspirin and the risk for cancerJAMA Oncol20162676276926940135
   PubMed Web of Science ®Google Scholar
• TangLHuHLiuHJianCWangHHuangJAssociation of non-steroidal anti-inflammatory drugs and aspirin use and the risk of head and neck cancers: a meta-analysis of observational studiesOncotarget2016740651966520727533449
   PubMedGoogle Scholar
• HuangXZChenYWuJAspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysisOncotarget2017834781479527902474
   PubMedGoogle Scholar
• EndoKYoonBIPairojkulCDemetrisAJSiricaAEERBB-2 over-expression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditionsHepatology200236243945012143054
   PubMed Web of Science ®Google Scholar
• SiricaAELaiGHEndoKZhangZYoonBICyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targetsSemin Liver Dis200222330331412360423
   PubMed Web of Science ®Google Scholar
• SiricaAELaiGHZhangZBiliary cancer growth factor pathways, cyclooxygenase-2 and potential therapeutic strategiesJ Gastroenterol Hepatol200116436337211357901
   PubMed Web of Science ®Google Scholar
• TakkoucheBEtminanMCaamañoFRochonPAInteraction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysisDrug Saf200225537337812020174
   PubMed Web of Science ®Google Scholar